Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 15/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554848 | 0.91 | CFD (0.60) | CFD | |
| SCHEMBL29545011 | 0.91 | CFD (0.60) | CFD | |
| SCHEMBL21752229 | 0.90 | CFD (0.52) | CFDGRIN2BLMNA | |
| SCHEMBL21752177 | 0.88 | CFD (0.51) | CFDGRIN2BLMNA | |
| SCHEMBL21790293 | 0.88 | CFD (0.51) | CFDGRIN2BLMNA | |
| SCHEMBL21752370 | 0.87 | CFD (0.50) | CFDGRIN2BLMNAPOLB | |
| SCHEMBL21752888 | 0.86 | CFD (0.49) | CFDGRIN2BLMNA | |
| SCHEMBL21752284 | 0.86 | CFD (0.49) | CFDLMNA | |
| SCHEMBL21752166 | 0.86 | CFD (0.49) | CFDGRIN2BLMNA | |
| SCHEMBL24966604 | 0.85 | CFD (0.43) | CFDGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841086-B1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3841086-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020041301-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | CFD 1/4885GRIN2B 3901/4885ALDH1A1 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.